Similar results were presented in bladder carcinoma HT1376 cells, in which CAPE treatment upregulated MT2A and HO-1 expressions and MT2A knockdown attenuated the activation of CAPE on HO-1 protein levels (Figure 5E). Here, MT2A is linked to urinary bladder carcinoma.